Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] ABL Bio (298380) – Kiwoom Securities | ABL301 Deprioritization · ABL001 Valuation · Grabody B Validity / 2026-02-02 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Defense Export Expansion · GR Turnaround · 2026E Upward / 2026-02-19 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | AI Data Center Backlogs · LTA · Earnings Visibility / 2026-05-11 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · Operating Leverage · Shareholder Returns / 2026-01-30 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · Supply Deficit · Valuation Appeal / 2026-03-04 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | ESS Revenue Surge · 4Q26 Turnaround · Physical AI Expansion with 46-Series & All-Solid-State / 2026-02-03 Research
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI Demand · Supply Tightness · Margin Expansion / 2026-08-11 Research
  • [IR] Samsung Electronics (005930) – Q2 2026 Earnings Presentation / 2026-07-30 IR Room

[Research] SK hynix (000660 / SKHY) – Shinhan | Memory ASP · Supply Tightness · Pricing Power / 2026-01-30

Posted on January 30, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Shinhan Securities

Analyst : Hyungtae Kim (RA: Hyesus Song)

Investment Rating : BUY (Maintained)

Target Price : 1,300,000 KRW (Raised)

Core Momentum : Severe supply-demand imbalances and depleted inventories are expected to sustain broad-based memory ASP increases, strengthening supplier pricing power and driving rapid margin and earnings expansion across DRAM and NAND.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 1,300,000 KRW (Based on Target P/B 3.5x applied to 2026F BPS of 345,704 KRW, Raised)
  • Investment Rating: BUY (Maintained)
  • 2026F Financial Outlook: Revenue 211.67 trillion KRW, Operating Profit 143.42 trillion KRW, Net Income 123.22 trillion KRW
  • Valuation Multiples: PER 4.9x, PBR 2.5x, EV/EBITDA 3.4x, ROE 68.3% (Based on 2026F)

🚀 2. [Market Opportunities & Business Outlook]

  • 4Q25 Review: Revenue reached 32.8 trillion KRW (+34.3% QoQ) and operating profit hit 19.2 trillion KRW (+68.4% QoQ), beating consensus estimates (Revenue 31.3 trillion KRW, OP 16.7 trillion KRW). DRAM operating margin hit ~68%, with NAND approaching 30%. Estimated B/G for DRAM/NAND stood at +0.7%/+10%, and ASP growth at +24.7%/+30.4%, beating prior expectations.
  • 1Q26 Preview: Operating profit is projected at 28.3 trillion KRW (+47.5% QoQ) on revenue of 44.1 trillion KRW (+34.4% QoQ). With limited B/G growth, ASPs are expected to surge by ~36%, driving operating margins up to 72.1% for DRAM and 41% for NAND.
  • Industry & LTA Dynamics: Amid reaffirmed hyperscaler investment commitments, supplier-led Long-Term Agreements (LTAs) are under discussion. Despite efforts to maximize output and enhance processes, tight supply conditions are expected to persist throughout the year with inventories near rock bottom.
  • Growth Drivers & Returns: Outlines reviewed shareholder return initiatives, business expansion via the AI subsidiary (AI Co.), and upcoming high-value product diversification directions for the second half.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst views SK hynix as an enterprise capturing explosive earnings growth fueled by severe supply shortages and broad ASP uptrends across all memory products, while leveraging strong cash generation to review shareholder remuneration and pursue high-value portfolio expansion. The analyst highlights earnings level-ups and supplier pricing power.

To verify this investment thesis, one should track whether 1Q26 results hit the projected revenue of 44.1 trillion KRW and operating profit of 28.3 trillion KRW with expanded margins, if supplier-driven LTA contracts are successfully formalized, and how high-value product diversification directions and shareholder return policies unfold. These indicators can be monitored through upcoming quarterly reports and regulatory filings via DART.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – iM Securities | Fixed Memory Pricing · Supply Shortage · Earnings Growth / 2026-01-30
Next Post: [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM · eSSD · Margin Expansion / 2026-01-30

Related Posts

  • [Research] SK hynix (000660 / SKHY) – iM Securities | DRAM Pricing · ADR Listing · Multiple Recovery / 2026-04-24 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · Operating Leverage · Shareholder Returns / 2026-01-30 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 6 Groundbreaking Visibility · Labor Negotiation · Rockville Revenue Recognition / 2026-04-02 Research
  • [Research] Alteogen (196170) – Hana Securities | Steady Milestone Inflows · Interpreting GSK’s Enhanze Deal · PGR Final Ruling Catalysts / 2026-05-13 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Product Mix Expansion · Pipeline Addition · Earnings Growth / 2026-07-28 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Product Mix Expansion · Pipeline Addition · Earnings Growth / 2026-07-28 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Hypothetical SDC Stake Monetization · North American ESS Acceleration · Valuation Appeal / 2026-01-19 Research
  • [Research] Samsung Electro-Mechanics (009150) – iM Securities | Valuation Reset · MLCC Price Hikes · Server Demand / 2026-07-31 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | MLCC Price Cycle · Customer Prepayments · Server Demand / 2026-08-11 Research
  • [Research] Samsung Electro-Mechanics (009150) – DS Investment & Securities | MLCC Price Leverage · Capacity Cannibalization · Earnings Upward Revisions / 2026-07-31 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28 Research
  • [Research] Samsung SDI (006400) – SK Securities | Plant Utilization Recovery · North America ESS Expansion · AMPC Benefits / 2026-04-29 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme